...
首页> 外文期刊>American Journal of Physiology >A new antidiabetic compound attenuates inflammation and insulin resistance in Zucker diabetic fatty rats
【24h】

A new antidiabetic compound attenuates inflammation and insulin resistance in Zucker diabetic fatty rats

机译:一种新的抗糖尿病化合物可减轻Zucker糖尿病脂肪大鼠的炎症和胰岛素抵抗

获取原文
获取原文并翻译 | 示例
           

摘要

Lu M, Patsouris D, Li P, Flores-Riveros J, Frincke JM, Watkins S, Schenk S, Olefsky JM. A new antidiabetic compound attenuates inflammation and insulin resistance in Zucker diabetic fatty rats. Am J Physiol Endocrinol Metab 298: E1036-E1048, 2010. First published February 16, 2010; doi:10.1152/ajpendo.00668. 2009. - Tissue macrophage inflammatory pathways contribute to obesity-associated insulin resistance. Here, we have examined the efficacy and mechanisms of action of a novel anti-inflammatory compound (HE3286) in vitro and in vivo. In primary murine macrophages, HE3286 attenuates LPS- and TNFα-stimulated inflammation. In Zucker diabetic fatty rats, inflammatory cytokine/chemokine expression was downregulated in liver and adipose tissue by HE3286 treatment, as was macrophage infiltration into adipose tissue. In line with reduced inflammation, HE3286 treatment normalized fasting and fed glucose levels, improved glucose tolerance, and enhanced skeletal muscle and liver insulin sensitivity, as assessed by hyperinsulinemic euglycemic clamp studies. In phase 2 clinical trials, HE3286 treatment led to an enhancement in insulin sensitivity in humans. Gluconeogenic capacity was also reduced by HE3286 treatment, as evidenced by a reduced glycemic response during pyruvate tolerance tests and decreased basal hepatic glucose production (HGP) rates. Since serum levels of gluconeogenic substrates were decreased by HE3286, it indicates that the reduction of both intrinsic gluconeogenic capacity and substrate availability contributes to the decrease in HGP. Lipidomic analysis revealed that HE3286 treatment reduced liver cholesterol and triglyceride content, leading to a feedback elevation of LDL receptor and HMG-CoA reductase expression. Accordingly, HE3286 treatment markedly decreased total serum cholesterol. In conclusion, HE3286 is a novel anti-inflammatory compound, which displays both glucose-lowering and cholesterol-lowering effects.
机译:卢M,帕苏里斯D,李鹏,弗洛雷斯·里弗罗斯J,弗林克JM,沃特金斯S,申克S,奥列夫斯基JM。一种新的抗糖尿病化合物可减轻Zucker糖尿病高脂大鼠的炎症和胰岛素抵抗。 Am J Physiol Endocrinol Metab 298:E1036-E1048,2010年。2010年2月16日首次发布; doi:10.1152 / ajpendo.00668。 2009年。-组织巨噬细胞炎症途径促成肥胖相关的胰岛素抵抗。在这里,我们已经研究了新型抗炎化合物(HE3286)在体外和体内的功效和作用机理。在原代鼠巨噬细胞中,HE3286可减轻LPS和TNFα刺激的炎症。在Zucker糖尿病性脂肪大鼠中,HE3286处理可降低肝脏和脂肪组织中炎症细胞因子/趋化因子的表达,巨噬细胞浸润到脂肪组织中也是如此。与减少炎症反应相一致,HE3286治疗可通过高胰岛素正常血糖钳夹研究评估正常化的禁食和进食葡萄糖水平,改善的葡萄糖耐量以及增强的骨骼肌和肝脏胰岛素敏感性。在2期临床试验中,HE3286治疗导致人体胰岛素敏感性增强。丙酮酸耐受性试验期间血糖反应降低和基础肝葡萄糖生成(HGP)速率降低证明,HE3286治疗还降低了糖原生成能力。由于HE3286可降低糖原异生底物的血清水平,因此表明内在糖原异生能力和底物可利用性的降低均有助于HGP的降低。脂质组学分析显示,HE3286治疗可降低肝胆固醇和甘油三酸酯含量,从而导致LDL受体和HMG-CoA还原酶表达的反馈升高。因此,HE3286治疗显着降低了总血清胆固醇。总之,HE3286是一种新型的抗炎化合物,具有降糖和降胆固醇的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号